NCT05209295 2026-01-12
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
Bristol-Myers Squibb
Phase 1 Terminated
Bristol-Myers Squibb
Assistance Publique - Hôpitaux de Paris
Bayer
National Institutes of Health Clinical Center (CC)
Debiopharm International SA
Janssen Research & Development, LLC
ANRS, Emerging Infectious Diseases